ATE403678T1 - Peptide, bestehend aus zwei funktionellen pth- domänen, die durch ein linkermolekül verknüpft sind, und derivate davon - Google Patents

Peptide, bestehend aus zwei funktionellen pth- domänen, die durch ein linkermolekül verknüpft sind, und derivate davon

Info

Publication number
ATE403678T1
ATE403678T1 AT99968197T AT99968197T ATE403678T1 AT E403678 T1 ATE403678 T1 AT E403678T1 AT 99968197 T AT99968197 T AT 99968197T AT 99968197 T AT99968197 T AT 99968197T AT E403678 T1 ATE403678 T1 AT E403678T1
Authority
AT
Austria
Prior art keywords
pth
derivatives
functional
linker molecule
peptides consisting
Prior art date
Application number
AT99968197T
Other languages
English (en)
Inventor
Thomas Gardella
Henry M Kronenberg
John T Potts Jr
Harald Jueppner
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Application granted granted Critical
Publication of ATE403678T1 publication Critical patent/ATE403678T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/635Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT99968197T 1998-12-31 1999-12-30 Peptide, bestehend aus zwei funktionellen pth- domänen, die durch ein linkermolekül verknüpft sind, und derivate davon ATE403678T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11457798P 1998-12-31 1998-12-31

Publications (1)

Publication Number Publication Date
ATE403678T1 true ATE403678T1 (de) 2008-08-15

Family

ID=22356116

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99968197T ATE403678T1 (de) 1998-12-31 1999-12-30 Peptide, bestehend aus zwei funktionellen pth- domänen, die durch ein linkermolekül verknüpft sind, und derivate davon

Country Status (7)

Country Link
US (1) US20080058505A1 (de)
EP (1) EP1147133B1 (de)
JP (1) JP2002533115A (de)
AT (1) ATE403678T1 (de)
AU (1) AU2486800A (de)
DE (1) DE69939275D1 (de)
WO (1) WO2000039278A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4486258B2 (ja) 1998-11-25 2010-06-23 ザ・ジェネラル・ホスピタル・コーポレイション ヒト副甲状腺ホルモンの改変、調製および使用
AU2023499A (en) 1998-12-31 2000-07-24 General Hospital Corporation, The Pth receptor and screening assay utilizing the same
AU7193501A (en) * 2000-07-10 2002-01-21 Us Health Multiple antigenic peptides immunogenic against streptococcus pneumoniae
AU2002339843B2 (en) 2001-07-23 2007-12-06 The General Hospital Corporation Conformationally constrained parathyroid hormone (PTH) analogs
DE50212514D1 (de) * 2002-08-06 2008-08-28 Aplagen Gmbh Synthetische Mimetika von physiologischen Bindungsmolekülen
US8088734B2 (en) * 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
MX353986B (es) 2007-08-01 2017-11-06 Massachusetts Gen Hospital Metodos de analisis y seleccion usando receptores acoplados a proteina g y composiciones relacionadas.
WO2010111617A2 (en) 2009-03-27 2010-09-30 Van Andel Research Institute Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use
JP5941040B2 (ja) 2010-05-13 2016-06-29 ザ ジェネラル ホスピタル コーポレイション 副甲状腺ホルモン類似体およびその使用
JP2014521594A (ja) * 2011-05-25 2014-08-28 アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニー 長持続期間デュアルホルモンコンジュゲート
US20200354428A9 (en) * 2013-06-23 2020-11-12 Wisconsin Alumni Research Foundation Analogues of parathyroid hormone (1-34) that function as agonists of the parathyroid hormone receptor-1 and display modified activity profiles
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
US12233115B2 (en) 2022-09-30 2025-02-25 Extend Biosciences, Inc. Long-acting parathyroid hormone

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) * 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4736866A (en) * 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
IL78342A (en) * 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
US4761406A (en) * 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
US5527772A (en) * 1987-10-20 1996-06-18 Holick; Michael F. Regulation of cell proliferation and differentiation using peptides
US5434246A (en) * 1992-03-19 1995-07-18 Takeda Chemical Industries, Ltd. Parathyroid hormone derivatives
US5814603A (en) * 1992-06-12 1998-09-29 Affymax Technologies N.V. Compounds with PTH activity
US5977070A (en) * 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
AU672790B2 (en) * 1992-07-15 1996-10-17 Novartis Ag Variants of parathyroid hormone and its fragments
CA2126299C (en) * 1994-06-20 2000-12-12 Gordon E. Willick Parathyroid hormone analogues for the treatment of osteoporosis
US6495662B1 (en) * 1998-10-22 2002-12-17 The General Hospital Corporation Bioactive peptides and peptide derivatives of parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHrP)
JP4486258B2 (ja) * 1998-11-25 2010-06-23 ザ・ジェネラル・ホスピタル・コーポレイション ヒト副甲状腺ホルモンの改変、調製および使用
WO2000031137A1 (en) * 1998-11-25 2000-06-02 The General Hospital Corporation Amino-terminal modified parathyroid hormone (pth) analogs
WO2000032771A1 (en) * 1998-11-30 2000-06-08 The General Hospital Corporation Pth1r and pth3r receptors, methods and uses thereof

Also Published As

Publication number Publication date
WO2000039278A8 (en) 2001-01-11
US20080058505A1 (en) 2008-03-06
EP1147133A4 (de) 2003-02-12
WO2000039278A2 (en) 2000-07-06
DE69939275D1 (de) 2008-09-18
EP1147133B1 (de) 2008-08-06
AU2486800A (en) 2000-07-31
EP1147133A2 (de) 2001-10-24
JP2002533115A (ja) 2002-10-08

Similar Documents

Publication Publication Date Title
ATE403678T1 (de) Peptide, bestehend aus zwei funktionellen pth- domänen, die durch ein linkermolekül verknüpft sind, und derivate davon
Bourne et al. A backbone linker for BOC-based peptide synthesis and on-resin cyclization: Synthesis of stylostatin 1
BRPI0407071B8 (pt) peptídeo purificado, seu método de produção e composição farmacêutica para o tratamento de distúrbios gastrointestinais
DK1144607T5 (da) Fremgangsmåde til præsentation af (poly)peptider/proteiner på bakteriofage partikler via disulfidbindinger
CA2395699A1 (en) NUCLEIC ACIDS, PROTEINS AND ANTIBODIES
WO2002057303A3 (en) Protein-protein interactions between shigella flexneri polypeptides and mammalian polypeptides
DE60230046D1 (de) Peptide, die atherosklerotische schädigungen binden
CY1107881T1 (el) Τροποποιημενα πεπτιδια ως θεραπευτικοι παραγοντες
IL195337A0 (en) Cyr61 compositions and methods
WO2002024222A3 (en) Ligands for g protein coupled receptors and methods of using them
PE20010516A1 (es) Peptidos ciclicos con afinidad mejorada por los receptores de somatostatina
DE602005019495D1 (de) Ligand für den Formylpeptidrezeptorähnlichen- 2 (FPRL2) G Protein gekoppelten Rezeptor und dessen Anwendung
WO2006083964A3 (en) Modified fusion molecules for treatment of allergic disease
ECSP055849A (es) Anticuerpo ("11c7") anti-nogo a y su uso farmacéutico
WO2004066933A3 (en) Compositions and methods for treating cancer using igsf9 and liv-1
Volz et al. Molecular characterization of metal-binding polypeptide domains by electrospray ionization mass spectrometry and metal chelate affinity chromatography
Popławska et al. Identification of a novel growth hormone releasing peptide (a glycine analogue of GHRP‐2) in a seized injection vial
WO2002026930A3 (en) Nucleic acids, proteins, and antibodies
Bunschoten et al. A general sequence independent solid phase method for the site specific synthesis of multiple sulfated-tyrosine containing peptides
Mokotoff et al. Caution in the use of 2‐iminothiolane (Traut's reagent) as a cross‐linking agent for peptides. The formation of N‐peptidyl‐2‐iminothiolanes with bombesin (BN) antagonist (d‐Trp6, Leu13‐ψ [CH2NH]‐Phe14) BN6− 14 and d‐Trp‐Gln‐Trp‐NH2
Pillai et al. A flexible method for preparation of peptide homo‐and heterodimers functionalized with affinity probes, chelating ligands, and latent conjugating groups
Decalf et al. A novel method to produce synthetic murine CXCL10 for efficient screening of functional variants
Biernat et al. Amino-Terminal Dimerization of Peptides on the Solid Support. Synthesis and Biological Activity of the Immunosuppressive HLA− DR Fragments Linked by Poly (ethylene glycol) s
ATE368750T1 (de) Screening-verfahren zum identifizieren von g- proteinen und anderen verbindungen,die die phosphodiesterase (pde)-aktivität beeinflussen
Percipalle et al. Structural characterization of synthetic model peptides of the DNA‐binding cI434 repressor by electrospray ionization and fast atom bombardment mass spectrometry

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties